Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19’s toll on the elderly and those with diabetes mellitus – Is vitamin B12 deficiency an accomplice?

Andrew Kien Han Wee

A R T I C L E   I N F O

Keywords: Vitamin B12 COVID-19 Diabetes mellitus Homocysteine One-carbon metabolism Sars-Cov-2 Elderly Immune system

A B S T R A C T

COVID-19 exacts a disproportionate toll on both the elderly and those with diabetes; these patients are more likely to require costly intensive care, longer hospitalisation, and die from complications. Nations would thus find it extremely difficult to either lift or sustain socially, economically, and politically damaging restrictions that keep this group of people safe. Without a vaccine, there is thus an urgent need to identify potential modifiable risk factors which can help manage overall fatality or recovery rates. Case fatality rates are highly variable between (and even within) nations; nutritional differences have been proposed to account significantly for this disparity. Indeed, vitamin B12 deficiency is a common denominator between the elderly and those with diabetes.

Introduction

The COVID-19 pandemic exacts a disproportionate toll on the elderly and those with diabetes mellitus (henceforth used interchangeably with “diabetes”); these patients are more likely to require costly intensive care facilities, stay longer in hospital, and die from COVID-19 [1–8]. With currently 703 million persons aged 65 years or older [9] and 422 million people having diabetes mellitus [10] globally, nations worldwide have instituted very costly social restrictions, curfews and lockdowns—especially to keep this vulnerable group of people safe. However, with socioeconomic costs mounting, governments now face the practical dilemma of either sustaining the restrictions or lifting them—with the ever-present risk of resurgent infections re-threatening this vulnerable group and overwhelming healthcare facilities. Indeed, short of a vaccine, its contagiousness and markedly different clinical presentations [11]—from the asymptomatic to the deadly—make COVID-19 a long-term constant threat.

Major clinical events include: atypical pneumonia; respiratory failure; thromboses; kidney diseases; cerebrovascular and neurological disorders; Kawasaki disease; multi-organ failure; and death [12,13]. Much of the above suggest an underlying cytokine storm [14] and systemic vasculitis [13].

Reported case fatality rates (CFRs) are highly variable. A French study of 1317 hospitalized COVID-19 patients with diabetes mellitus (with an 88.5% predominance of type-2 diabetes mellitus (T2DM)) showed a case fatality of 10.6% (by day 7 of hospitalization); combining both outcomes of “death” and “tracheal intubation for assisted mechanical ventilation” (within 7 days of admission), the prevalence rose

Abbreviations: ACE, Angiotensin-converting enzyme; ALT, Alanine aminotransferase; B12, Vitamin B12; BMI, Body mass index; CFR, Case fatality rate; CI, Confidence intervals; COVID-19, Coronavirus disease caused by SARS-CoV-2; CD4+, T helper cells; CD8+, Cytotoxic T cells; CRP, C-reactive protein; Diabetes, Diabetes mellitus; eGFR, Estimated glomerular filtration rate; HCV, Hepatitis C virus; IL, Interleukin; IFN-γ, Interferon gamma; IRES, Internal ribosomal entry site for the hepatitis C virus; NHANES, National Health And Nutrition Examination Survey; NK cell, Natural killer cell; nsp, Non-structural protein of SARS-CoV-2; OR, Odds ratio; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; SD, Standard deviation; SOC, Standard of care; SVR, Sustained viral response; T2DM, Type-2 diabetes mellitus; TNF-α, Tumour necrosis factor alpha; UMFA, Unmetabolized folic acid.

* Address: Marine Parade Polyclinic Blk 80 Marine Parade Central, #01-792, Singapore 440080, Singapore.

E-mail addresses: andrew.wee@singhealth.com.sg, aweekh@singnet.com.sg.

https://doi.org/10.1016/j.mehy.2020.110374

Received 14 June 2020; Received in revised form 20 August 2020; Accepted 22 October 2020
Without restriction to old age or diabetes, globally reported CFRs are lower. As of May 2020, the highest case fatality rate of 9.6% was in Europe, followed by 5.9% in North America, and 3.5% in Asia [3]. The Diamond Princess cruise ship, where 100% of the population (mean age of 58 years) was tested, had a corrected infection fatality rate of 1.3% [8]. In contrast, the CFR of severe seasonal flu is only 0.1% [1].

In particular, among the nations with more than 1000 documented cases of COVID-19, Singapore reports the lowest CFR of only 0.07% [3]. As of 01 June 2020, with its extensive contact tracing and testing of suspected cases, Singapore had up to 35,292 cumulative cases of COVID-19 infections, but with only 7 patients receiving intensive care at that time and an official case fatality of only 23 individuals, with men outnumbering women (16 men (70%) vs. 7 (30%) women) [3]. Notably, 33,027 (94%) of the infected comprised relatively young blue-collar non-citizen workers residing in dormitories. Predominantly from South-, East-, and Southeast Asia, many of these workers had, in contrast, mild or no symptoms and none had died from COVID-19 at the time of writing [3].


d To 29% [5].

Without restriction to old age or diabetes, globally reported CFRs are lower. As of May 2020, the highest case fatality rate of 9.6% was in Europe, followed by 5.9% in North America, and 3.5% in Asia [3]. The Diamond Princess cruise ship, where 100% of the population (mean age of 58 years) was tested, had a corrected infection fatality rate of 1.3% [3]. In contrast, the CFR of severe seasonal flu is only 0.1% [1].

In particular, among the nations with more than 1000 documented cases of COVID-19, Singapore reports the lowest CFR of only 0.07% [3]. As of 01 June 2020, with its extensive contact tracing and testing of suspected cases, Singapore had up to 35,292 cumulative cases of COVID-19 infections, but with only 7 patients receiving intensive care at that time and an official case fatality of only 23 individuals, with men outnumbering women (16 men (70%) vs. 7 (30%) women) [3]. Notably, 33,027 (94%) of the infected comprised relatively young blue-collar non-citizen workers residing in dormitories. Predominantly from South-, East-, and Southeast Asia, many of these workers had, in contrast, mild or no symptoms and none had died from COVID-19 at the time of writing [3].

Established reasons for the higher COVID-19 complications in the elderly and those with diabetes include glycaemic instability, impaired T-cell response, and pre-existing comorbidities (like obesity, cardiovascular and kidney diseases) [1,3]. Postulated reasons include chronic low-grade inflammation (that is associated with increased cytokines) and factors associated with viral entry (like ACE-2 expression) [1,3,11,12].

Aside from old age and diabetes, other prognostic markers for poor COVID-19 outcomes include: higher BMI [5], ALT [24], CRP [5], CD4+ : CD8+ ratios [25], pro-inflammatory cytokine levels (eg IL-2 and TNF-α) [4,24,25], D-dimer levels [24,25], and IFN-γ levels [24]: lower eGFR [5], peripheral counts of CD4+ and CD8+ T cells [25], and lymphocyte count [5]; and the male gender [7]. However, all these risk factors are either non-modifiable or merely reflect irreversibly late sequelae.

Recently, it has been proposed that nutrition is partly responsible for these wide differences in COVID-19 death rates seen between (and even within) countries [3]. Nutrition can certainly affect the immune system’s ability to protect against viral infections [28,29]; elderly malnutrition in COVID-19 infections has been described in a Chinese study. This study of 182 elderly (age ≥65 years) COVID-19 patients using the Mini-Nutritional-Assessment score showed 52.7% to be “malnourished” and a further 27.5% to be “at risk of malnutrition” [30]. Regression risk in the study also showed diabetes mellitus to be an independent risk factor for malnutrition (OR: 2.12; 95% CI: 1.92–3.21; P = 0.006) [30].

There are now more than 40 registered studies looking at the role of vitamins in COVID-19 [31]. However, most are focused on vitamins C, D and the mineral zinc—and vitamin B12 deficiency’s impact on COVID-19 are currently unclear.
Hypothesis

We therefore sought to review the hypothesis that vitamin B12 deficiency, along with its resultant defects in one-carbon metabolism—a central group of vitamin B12-folate-homocysteine dependent biochemical reactions that are crucial for wide-ranging aspects of DNA synthesis, cellular regulation and body repair [32,33]—could be a major modifiable risk factor in COVID-19 morbidity and mortality in the elderly and those with diabetes mellitus.

Evaluation of the hypothesis

Search strategy and selection criteria

To review the state of the art pertaining to vitamin B12 deficiency (henceforth known as “B12 deficiency”) and COVID-19, an on-line literature search on “Pubmed”, “Google”, and the clinical trials registries “ClinicalTrials.gov” was done using the following MeSH and free text search terms (associated with B12 deficiency): “B12 deficiency”; “B12”; “folate”; “vitamin”; “homocysteine”; “one-carbon metabolism”; and “metformin”, which were first used singly, and subsequently matched, each in turn, with the terms (associated with COVID-19): “COVID”; “COVID-19”; and “Sars-Cov-2”. A third round of searches ensued with the terms (comprising biomarkers of poor COVID-19 outcomes, or the means by which the virus gains entry): “prognostic factors”; “elderly”; “older”; “diabetes”; “obesity”; “BMI”; “gender”; “tnf alfa”; “interleukin”; “ifn gamma”; “cd4 cd8”; “lymphocytes”; “nk cell”; and “ace” added in turn to the first round of searches. Only published articles in English were shortlisted and, where appropriate, filters were used to extract only reviews. In the event of similar reviews, the most recent or most comprehensive was chosen. Reference lists from journal articles and book chapters resulting from the online-search, together with the author’s past reading on the topic, were also used. Given the unprecedented rapid pace of COVID-19 research, preprints were judiciously allowed in the search and qualified as such in citations.

B12 deficiency is associated with the elderly and those with diabetes

Old age per se associates with B12 deficiency; deficiencies have been reported in up to 15% of elderly populations in the USA and Europe [34–37]. This has been attributed to B12 malabsorption (like pernicious anaemia and atrophic gastritis) [34–37], to poorer nutrition or diets weighted on vegetables [38], or to increased urinary and gut loss of B12 [39] through age-related defects in the megalin-cubulin-aminonless complex of receptors (that are responsible for reclaiming transcobalamin-bound B12 from the glomerular filtrate and intrinsic-factor-bound B12 in the gut) [40–42].

Diabetes further associates with B12 deficiencies worldwide. A U.S. primary-care services study [43] showed that 22% of outpatients had metabolically confirmed vitamin B12 deficiency. Similarly, the prevalence of B12 deficiency was 28.1% in a cross-sectional study of 550 type-2 diabetes patients in four primary care centres in the Netherlands [44]. Our polyclinic’s pilot cross-sectional study of 56 elderly patients with type-2 diabetes showed that 43% were vitamin B12 deficient, of whom 75% had concurrent hyperhomocysteinaemia [45].

Several reasons for B12 deficiency in T2DM have been proposed. The drug “metformin” is the mainstay of type-2 diabetes treatment [46,47] and there is consistently strong evidence of its association with B12 deficiency [48–51]. Metformin reportedly disrupts calcium-dependent intestinal absorption of vitamin B12 and calcium supplementation was shown to reverse this [52]. The frequent use of proton-pump inhibitors or histamine H2 receptor antagonists among these patients [38,53], especially as gastric-acid-reducing adjuncts to aspirin therapy (used in the secondary prevention of cardiovascular events in diabetes [54,55]), could also reduce the ability to digest B12 from food [56].

B12 deficiency and one-carbon metabolism

Vitamin B12 has critical functions (through one-carbon metabolism) (Fig. 1) in both cellular and humoral immunity [29,57]. B12 is a cofactor for methionine synthase and B12 deficiency results in the wasted accumulation (“trapping”) of 5-methyl tetrahydrofolate that is formed by the rate-limiting but irreversible reaction of the enzyme “methyl-
omitetrathydrofolate reductase” (MTHFR) [57]. This could result in a “secondary folate deficiency” with impairments in thymidine and purine synthesis, ultimately impacting DNA and RNA synthesis that are vital for proper cell division, haematopoesis and hence immunity [29,57,58],

B12 deficiency and the immune system

A Japanese study [59] on 11 B12-deficient patients and 13 non-deficient controls demonstrated that B12-deficient patients had statistically higher CD4+:CD8+ ratios (P < 0.05); lower NK cell activity (P < 0.01); reduced CD8+ cell (cytotoxic T cell) count (P < 0.01); and lymphopaenia (P < 0.01) (all markers implying lowered immunity). After only a 2-week administration of B12 (using methylcobalamin 500 µg/ day) in both patients and 8 of the initial 13 controls, B12-deficient patients demonstrated significant improvements in leucopaenia (P < 0.05); lymphopaenia (P < 0.05); CD8+ cell count (P < 0.05); and NK cell activity (P < 0.01). Even healthy controls had a better immune profile after B12 administration as evidenced by increased lymphocyte and CD8+ cell counts (both, P < 0.05)—suggesting anti-viral immunological benefits at B12 levels beyond normally accepted ranges. The authors posited that B12 prevents the apoptosis of lymphocytes, especially the CD8+ cells [59].

A later prospective Turkish study on 30 B12-deficient patients with pernicious anaemia also showed restoration in lymphocyte counts, NK cell activity and CD4+:CD8+ ratios after intramuscular administration of cyanocobalamin [60]. In addition, this study demonstrated increase in the levels of additional anti-viral components of the immune system, namely: complements C3 and C4, and immunoglobulins.

B12 deficiency and the microbiome in the gut

Like us, human gut microbes that support our gut barrier also require B12 as a cofactor for metabolism [29]. Moreover, rather than contribute to our B12 levels, these human microbes have multiple corrinoid (B12-like)-dependent enzymatic functions that make them likely competitors for our dietary cobalamin; a shortage of which potentially affects the proper balance of gut microbial communities (termed “gut dysbiosis”) and ultimately our health. Elderly people have lower gut microbiome diversity and beneficial microbes like Bifidobacterium [61]. A senescent gut thus lends itself to pathological bacteria (pathobiont) overgrowth, increased gut permeability to bacteria and toxins, and ultimately increase proinflammatory cytokines [61]. In addition, administration of Bifidobacterium lactis into 30 healthy elderly volunteers showed improved anti-viral NK-cell activity [62]. There is also evidence of a bidirectional “gut-lung axis” whereby microbiomes between lung and gut affect each other [63], in keeping with the respiratory and gastro-intestinal clinical manifestations of COVID-19. Indeed, alterations in gut microbiota correlating with disease severity have been described in 15 patients with COVID-19 [64].

B12 deficiency and obesity

Obesity, a prevalent non-modifiable risk factor for COVID-19 complications [5], associates inversely with both B12 [65] and folate levels [66] and directly with homocysteine levels [67]. A nationally representative sample of 9,075 U.S. adults showed significantly higher odds of obesity (defined as BMI ≥ 30 kg/m²) with lower quartiles of B12 levels (P for trend < 0.001) [65]; whilst a study on 1462 pregnant Korean women showed consistent negative correlation between BMI
and serum folate in mid- and late pregnancy ($P = 0.001$ and $0.024$, respectively). A Danish study on 118 patients in 2018 showed a positive correlation of BMI with homocysteine ($P = 0.005$) [67]. With regard to visceral obesity, a Turkish case-control study (comprising 45 patients with non-alcoholic fatty liver disease vs. 30 healthy controls) showed a significant negative correlation of B12 levels with both ALT levels and the grade of liver disease, as well as significantly lower B12 levels in the cases compared with controls ($P < 0.05$) [68].

**B12 deficiency extends its reach through homocysteine**

Homocysteine is a metabolic consequence of B12 deficiency (and also folate imbalance as discussed below). Renally cleared [69], it has been linked to adverse cardiovascular and neurocognitive outcomes [70]. Like adverse COVID-19 complications, homocysteine has also been associated with the male gender [70,71] and higher D-dimer levels (a marker of thrombosis and coagulopathy seen in COVID-19) [13,72].

Indeed clinically, it was recently published that hyperhomocysteinaemia (defined in the paper as greater than $15.5 \mu M/L$) was significantly associated with adverse pulmonary progression on CT imaging in 273 COVID-19 patients ($P < 0.05$ for both univariate and logistic regression analyses) [75], lending weight to its role in COVID-19 morbidity.

It was also recently described that the SARS-Cov-2 virus has a non-structural protein (nsp14) that is in fact a viral methyltransferase (specifically: guanidine-N7-methyltransferase) [76,77]. This enzyme likely uses the host’s S-adenosylmethionine for methylation of mRNA caps (a process believed to be essential for viral replication), potentially generating homocysteine over and above that from our own human methyltransferase (and perhaps leaving less for say methylation of neural myelin)—especially in the presence of B12 deficiency [58,76,77] (Fig. 1).

**B12 as an adjunct to antiviral therapy**

As an RNA virus, a significant portion of the Sars-Cov-2 genome codes for a main polypeptide protease (MPro), that is a key enzyme for the virus’ replication and thus an attractive target for potential anti-viral drugs [78]. Computer-aided molecular screening of the full array of FDA-approved drugs (with the aim of repurposing for the use against MPro), ranked vitamin B12 in the 4th position and a potentially safe drug to be repurposed for COVID-19 therapy [79]. Benchmarked against curcumin (a well-known [79] and stronger inhibitor of MPro than hydroxychloroquine [80]), vitamin B12 had a relative docking affinity for MPro that is 1.99 times better than curcumin (even rivalling ribavirin’s 2nd-placed affinity of 2.01 times). A separate computational study, a preprint nevertheless, reports that B12 potentially inhibits another aspect of the Sars-Cov-2 virus: that of its non-structural protein12 (an
RNA-dependent-RNA polymerase that is also vital for the virus’ replication [81].

The concept of B12 as an adjuvant or adjunct to antiviral therapy is not new, for a precedent exists in its activity against the Hepatitis C virus (HCV)—itself also a mutation-prone positive-sense single-stranded RNA virus, against which no vaccine yet exists [82]. HCV requires an internal ribosomal entry site (IRES) to mediate the initiation of its translation (and hence its replication process); B12 has been shown to inhibit IRES [83]. Based on this finding, two randomized controlled trials—an Italian followed by an Iranian [84,85]—reported the vitamin’s ability to improve rates of sustained viral response (SVR) when added to pegylated interferon-α-plus-ribavirin combined therapy, the erstwhile standard of care (SOC) for hepatitis C infections (from 2001 to 2011) [85]. On its own, SOC yields a less-than-perfect SVR of only 40–50% in the most-difficult-to-treat of the HCV genotypes (i.e. genotype 1) [84].

In the Italian study [84] on 94 patients (divided equally between intervention (Vitamin B12 + SOC) and control groups (SOC only)), SVR was achieved in 72% receiving intervention compared to only 38% receiving control; a 34% improvement in SVR (P = 0.001). Furthermore, this improvement in SVR through intervention was more pronounced in patients who also had the refractory HCV genotype 1 (41%, P = 0.003) or the highest baseline viral load (38%, P = 0.001). In the Iranian trial [85] on 36 patients receiving intervention (B12 + SOC) vs. 38 controls (SOC only), SVR was achieved in 80% of patients on intervention compared to only 68% of those on control (P = 0.0001). This study also demonstrated significantly reduced treatment side effects and dropout rates in the intervention arm (P = 0.0001).

Nevertheless, pegylated interferon and ribavirin have been supplanted by direct-acting antivirals which yield superior SVRs—and hence the use of B12 as an adjunct to treating HCV infection in clinical practice was a lost opportunity [86,87].

B12 and COVID-19 (emerging studies)

Currently, 2 other emerging studies point to defective one-carbon metabolism and poor COVID-19 outcomes. The first study (a preprint) comprised 43 COVID-19 patients aged ≥50 years, 17 of whom received a combination of vitamin D, magnesium and vitamin B12. It showed significantly lower odds of needing “oxygen therapy” and/or “intensive care support” (OR: 0.152; 95% CI: 0.025–0.930; P = 0.041) [88]. The second, an Israeli cohort of 162 patients, showed that lower folate levels consistently associated with increasing stages of COVID-19 severity (P = 0.005). Interestingly, higher levels of vitamin B12 was associated with increased severity of COVID-19 (P = 0.039) [89]. However, this paper did not publish multivariable analyses, nor did the authors explore statistically the potential interaction between folate and B12 [89].

B12 deficiency and the need for one-carbon metabolism to be balanced and fine-tuned

Nevertheless, the findings in the Israeli publication above highlights the clinical importance of an optimal balance between B12 and folate. Folate supplementation in the presence of B12 deficiency is known to both mask the haematological, but yet potentially exacerbate the neurological aspects of B12 deficiency [58,90]. Excessive folate intake from synthetic folic acid supplements (or food fortification) manifests as unmetabolized folic acid (UMFA). UMFA was detected in one-third of elderly participants in the 1999–2002 U.S. NHANES and, in the presence of low B12 levels, UMFA was associated with lower cognitive test scores and lower mean red blood cell volume in seniors [90]. Moreover, from this NHANES data, it was observed that in the presence of B12 deficiency, higher homocysteine levels (and methylmalonate levels) occurred when folate levels were high [90,91]. Another American study on 105 healthy postmenopausal women revealed that 78% of them had detectable plasma UMFA, and that these women with detectable UMFA had 23% lower NK cell cytotoxicity compared with those without (P =

Direction of arrows denote published associations discussed in the text; not necessarily causality.

Fig. 3. Pictorial summary of vitamin B12 deficiency’s association with biomarkers of adverse COVID-19 outcomes (refer to text for details). AT₁R, angiotensin II type 1 receptor; NAFLD, non-alcoholic fatty liver disease; MPro, main polypeptide protease of Sars-Cov-2; nsp12, non-structural protein12 of Sars-Cov-2 (an RNA-dependent-RNA polymerase).
of type-2 diabetes mellitus with metformin recommend the periodic possible confounder in COVID-19 mally tuned). homocysteine as a gauge that one-carbon-metabolism has been opti
rocognitive and haematological consequences [38,53] . Currently, the patients and those with diabetes mellitus through possible adverse neu
tropathy. However, these are insidious (hence difficult to recognize), late, and sadly often irreversible sequelae of B12 deficiency—and the guidelines fall short of the annual screening that was proposed almost 50 years ago [51]. Indeed, regular screening for metformin-associated B12 deficiency in diabetes is still wanting; a 2019 Irish audit of 241 patient records (within both primary and specialist care) found that 56 (23%) patients were never screened for B12 levels [94].

Consequences of the hypothesis and discussion

Vitamin B12 deficiency is a prevalent disorder that should be addressed and prevented in its own right. In view of this hypothesis and the COVID-19 crisis, we recommend that it should be more urgently addressed; the elderly and those with diabetes mellitus should be regularly screened for deficiencies, whereupon B12 levels should be optimized and balanced carefully in tandem with folate (perhaps using homocysteine as a gauge that one-carbon-metabolism has been optimally tuned).

Urgent research is needed to explore B12 deficiency’s role as a possible confounder in COVID-19’s devastating toll on the elderly and those with diabetes. As such, current research and clinical trials could add the testing of vitamin B12, folate and homocysteine levels into their protocols. Where possible, holotranscobalamin and methylmalonic acid levels could be included as better supplementary biomarkers of B12 deficiency because diagnosing deficiency using B12 levels alone has problems with sensitivity and specificity [84,95–97]. For example, peripheral/serum B12 levels could be falsely elevated in liver disease [84] and myeloproliferative diseases [95]—despite true metabolic B12 deficiencies—leading to underdiagnoses of deficiencies [95].

If the hypothesis is indeed true, further research should also factor in and adjust for functional genetic polymorphisms in one-carbon metabolism (eg DFR19bp6 90) and MTHFR67TC → T [90]) as well as the use of metformin (given emerging evidence of metformin’s association with better COVID outcomes [5,89,99] that is seemingly at odds with its association with B12 deficiency [48–50]). Going beyond deficiency in B12, further research could also include finding the optimal therapeutic levels of B12 (vis-à-vis folate and homocysteine levels)—either as an adjuvant to mainstream treatments or by itself—against COVID-19.

Summary and conclusion

This review shows that B12 deficiency associates in multiple areas very similar to where COVID-19 exerts its damaging effects: immunologically (innate and adaptive; cellular and humoral responses; and inflammation); microbiologically (gut microbiome); haematologically (coagulation); and endothelial cell signalling (more inflammation). These associations have the potential to converge, synergise and finally add to the disproportionate toll COVID-19 inflicts on the elderly and those with diabetes. There is also emerging data that B12 per se could interfere with Sars-Cov-2 replication, adding a potential therapeutic dimension. B12 deficiency is thus a possibly modifiable (and certainly avoidable) risk factor in our fight against COVID-19 (Fig. 3).

Why B12 deficiency still exists

Vitamin B12 deficiency poses an already-existing risk in older patients and those with diabetes mellitus through possible adverse neurocognitive and haematological consequences [38,53]. Currently, the American [46] and Singaporean [93] 2017 guidelines on the treatment of type-2 diabetes mellitus with metformin recommend the periodic measurement of vitamin B12 levels and their supplementation if necessary, particularly in patients with “anaemia or peripheral neuropathy”. However, these are insidious (hence difficult to recognize), late, and sadly often irreversible sequelae of B12 deficiency—and the guidelines fall short of the annual screening that was proposed almost 50 years ago [51]. Indeed, regular screening for metformin-associated B12 deficiency in diabetes is still wanting; a 2019 Irish audit of 241 patient records (within both primary and specialist care) found that 56 (23%) patients were never screened for B12 levels [94].

References

1. Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc 2020;68:926–9.
2. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;4:395–403.
3. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? a meta-analysis. Diabetes Metab Syndr 2020;4:535–45.
4. Angelidou AM, Belanger MJ, Mantzoros CS. COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism 2020;154245.
5. Carzou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020.
6. Desai R, Singh S, Parekh T, Sachevleva S, Sachdeva R, Kumar G. COVID-19 and diabetes mellitus: a need for prudence in elderly patients from a pooled analysis. Diab Metab Syndr: Clin Res Rev 2020;14:685–9.
7. Li X, Xu S, Yu M, Wang Ke, Tao Yu, Zhou Y, Shi J, Zhou M, Wu Bo, Yang Z, Zhang C, Yue J, Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110-8. https://doi.org/10.1016/j.jaci.2020.04.006.
8. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang Li, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019

Useful website

National Institute of Health-Office of Dietary Supplements. Vitamin B12, Fact Sheet for Health Professionals. Available at: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/.

Disclaimer

The opinions expressed by the author of this manuscript does not necessarily reflect the official position of the institutions with which the author is affiliated to, or the funder.

Open researcher and contributor identification numbers

0000000236801614 Andrew Kien Han Wee.

Declaration of Competing Interest

The author declares no known competing financial interest or personal relationship that could have appeared to influence the work reported in this paper.

Acknowledgement

I extend my deepest gratitude to Ms. Fion Farn of Duke-NUS Centre for Clinician-Scientist Development (CCSD) for her administrative support.

Sources of support

1. ExxonMobil-NUS Research Fellowship for Clinicians, 2014.
2. National Medical Research Council Clinician Investigator Salary Support Programme. Reference Number: NMRC/CISSP/2014/030.
3. Duke-NUS Centre for Clinician-Scientist Development (CCSD) Khoo Scholars Program 2018.

Ethics approval

Not applicable.

Author’s contribution

Andrew Kien Han Wee is responsible for all aspects of this manuscript.

A.K.H. Wee

Medical Hypotheses 146 (2021) 110374

6
A.K.H. Wee

Rocco A, Compare D, Coccoli P, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut 2013;62:766–73.

Mokhtare M, Zeidabadi A, Bahardoust M, Safari S, Barati M, Agah S, Motavaf M. The efficacy of adding vitamin B12 to pegylated interferon and ribavirin treatment in Hepatitis C virus patients regarding the host and viral prognostic factors. BMAT [Internet]. 28Feb.2019;6(2):3016-2. Available from: http://www.bmat.org/index.php/BMAT/article/view/524. Accessed on 16 Aug 2020.

Chae HJ, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Sci World J 2013;2013:704912.

Tillmann HL. Vitamin(s) the magic bullet against hepatitis C. Expert Rev Anti Infect Ther 2012;10:1273–7.

Tan CW, Ho LP, Kalimuddin S, et al. A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DBM) on progression to severe outcome in older COVID-19 patients, medRxiv (2020), p. 2020.2006.2001.212334.

Hedman E, Wasserstrom Y, Segev A, et al. Clinical characterization of 162 COVID-19 patients in Israel: preliminary report from a large tertiary center. Isr Med Assoc J 2020;22:271–4.

Selhub J, Rosenberg IH. Excessive folic acid intake and relation to adverse health outcome. Biochimie 2016;126:71–8. https://doi.org/10.1016/j. biochi.2016.04.010.

Selhub J, Morris MS, Jacques PF, Rosenberg IH. Folate-vitamin B-12 interaction in relation to cognitive impairment, anemia, and biochemical indicators of vitamin B-12 deficiency. Am J Clin Nutr 2009;89:702s–6s.

Troen AM, Mitchell B, Sorensen B, et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006;136:189–94.

Ministry of Health, Singapore. Agency for Care Effectiveness (ACE) Appropriate Care Guide. Oral glucose-lowering agents in type 2 diabetes mellitus - an update. Version current 03 July 2017. Internet: http://www.ace-hsa.gov.sg/orour-guidance/oral-glucose-lowering-agents-in-type-2-diabetes-mellitus-an-update.html (accessed 27 Mar 2019).

Mukhtar M, Sherry D, Keever L, McHugh CM. Metformin-induced B12 deficiency: still relevant today. Irish J Med Sci (1971-) 2020;189:409–10.

Cinmmer H, Serinkan Cinmmer BF, Cekdemir D, Aydemir B, Tamer A, Yazar H. Diagnosis of vitamin B12 deficiency in patients with myeloproliferative disorders. J Investig Med 2015;63:636–40.

Nexo E, Hoffmann-Lucke E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. Am. J. Clin. Nutr. 94 (2011), pp. 359s-365s.

Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies, Am J Clin Nutr 94 (2011), pp. 666S–672S.

Luo P, Qiu L, Liu Y, et al., Metformin Treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am. J. Trop. Med. Hyg. (2020).

Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract 2020;164:101813.